Atectura® の実世界環境における 24 週間の前向き、非盲検、多施設、単群 rPMS 研究
Atectura® (QMF149 150/80 μg o.d.、QMF149 150/ 160 μg o.d. および QMF149 150/320 μg o.d. Breezhaler 経由)
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.
調査の概要
状態
条件
詳細な説明
The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Busan、韓国、48108
- Novartis Investigative Site
-
Gyeongsangnam Do、韓国、51353
- Novartis Investigative Site
-
Jeju City、韓国、63241
- Novartis Investigative Site
-
Seoul、韓国、05505
- Novartis Investigative Site
-
Seoul、韓国、04763
- Novartis Investigative Site
-
Seoul、韓国、06273
- Novartis Investigative Site
-
Seoul、韓国、137 707
- Novartis Investigative Site
-
Taegu、韓国、41944
- Novartis Investigative Site
-
Ulsan、韓国、44033
- Novartis Investigative Site
-
-
Dalseo gu
-
Daegu、Dalseo gu、韓国、42602
- Novartis Investigative Site
-
-
Gangneung si
-
Kangwon Do、Gangneung si、韓国、210 711
- Novartis Investigative Site
-
-
Gangwon-do
-
Wŏnju、Gangwon-do、韓国、26426
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国、10380
- Novartis Investigative Site
-
Guri-si、Gyeonggi-do、韓国、11923
- Novartis Investigative Site
-
-
Gyeongsangnam-do
-
Jinju、Gyeongsangnam-do、韓国、52727
- Novartis Investigative Site
-
-
Jeollabuk-do
-
Jeonju、Jeollabuk-do、韓国、54907
- Novartis Investigative Site
-
-
Jeonlabuk Do
-
Iksan Si、Jeonlabuk Do、韓国、54538
- Novartis Investigative Site
-
-
Korea
-
Daejeon、Korea、韓国、35015
- Novartis Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.
説明
Inclusion Criteria:
- Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
- Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)
Exclusion Criteria:
- Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
- Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
- Patients participating in other interventional clinical trials
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Atectura inhalation capsule (150/80ug)
Indacaterol acetate/Mometasone furoate; 150/80ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/160ug)
Indacaterol acetate/Mometasone furoate; 150/160ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
|
Atectura inhalation capsule (150/320ug)
Indacaterol acetate/Mometasone furoate; 150/320ug |
There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events and serious adverse events
時間枠:24 weeks
|
Incidence of AE and SAE will be collected |
24 weeks
|
|
Incidence of unexpected adverse events and unexpected serious adverse events
時間枠:24 weeks
|
Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label |
24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
change from baseline in trough FEV1
時間枠:Baseline, week 12
|
Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. |
Baseline, week 12
|
|
change from baseline in ACT score
時間枠:Baseline, week 12
|
The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement. |
Baseline, week 12
|
|
Effective rate and ineffective rate by investigator assessment
時間枠:week 12
|
Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment |
week 12
|
|
Baseline characteristics of patients showing adverse events/adverse drug reactions
時間枠:24 weeks
|
The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
24 weeks
|
|
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
時間枠:12 weeks
|
Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations |
12 weeks
|
|
Baseline characteristics of patients in relation to the investigator assessment
時間枠:12 weeks
|
Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations. |
12 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。